Novo Nordisk on Wednesday said its fourth-quarter profit surged by nearly two-thirds, driven by the popularity of its weight-loss drugs that have made it.
Novo Nordisk is on to a real winner with its popular weight-loss drug Wegovy. The company's market capitalization climbed past $500 billion early Wednesday.
Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $109.02, but opened at $112.15. Novo Nordisk A/S shares last traded at $115.27, with a volume of 3,686,417 shares changing hands. Wall Street Analysts Forecast Growth A number of research firms […]
Nicolet Advisory Services LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 109.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,163 shares of the company’s stock after buying an additional 1,654 shares during the quarter. Nicolet […]